IpIBA seminar series 2022/2023“Exploiting nanobodies targeting ABCC3 for glioblastoma immunoguided applications.”
Glioblastoma is the most aggressive primary brain tumor in adults. Efficiency of current diagnostic methods and therapeutic strategies of glioblastoma is narrowed by the presence of the molecular-restrictive blood-brain barrier (BBB), and the delayed translation of relevant biomarkers into clinical practice. New efforts emerge towards a personalized medicine, based on molecularly matched formulations against specific tumor biomarkers of this heterogeneous tumor. Due to their molecular features, nanobodies emerge as novel promising immunotargeted tools for glioblastoma.
Square:
CIBA, main meeting room, and online via zoom meeting
Importantly, places are limited: 100 in person and 100 online. If you participate in person, there is no need to register online.
Sign up here